When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Rivaroxaban - Wikipedia

   en.wikipedia.org/wiki/Rivaroxaban

   Rivaroxaban. 2 / 3 ⁠ metabolized in liver and ⁠ 1 / 3 ⁠ eliminated unchanged [4] Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. [8] Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial ...

3. Medicare announces lower prices on 10 common, high-cost drugs

   www.aol.com/news/first-time-medicare-cuts-prices...

   Here are the negotiated prices for the drugs, based on a 30-day supply: Eliquis, a blood thinner from Bristol Myers Squibb and Pfizer: $231 negotiated price, down from $521 list price. Xarelto, a ...

4. 10 prescription drug prices are dropping in 2026: Here are ...

   www.aol.com/10-prescription-drug-prices-dropping...

   Stelara. Stelara by Janssen Biotech, Inc. is used to treat psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. The 2026 list price will drop 66% from $13,836 for a 30-day ...

5. Factbox-Top Medicare drugs headed for price cuts - AOL

   www.aol.com/news/factbox-top-medicare-drugs...

   Xarelto. Eliquis rival Xarelto from Johnson & Johnson cost Medicare more than $6 billion between June 2022 and May 2023. The bloodthinner, which was used to treat 1.3 million enrollees, can lower ...

6. Direct factor Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

   Medical use. Direct factor Xa inhibitors include rivaroxaban, apixaban and edoxaban, and are types of direct oral anticoagulant (DOAC), which are blood thinning drugs, one of the classes of antithrombotic drugs. [4][5][6] They are commonly prescribed to treat and prevent blood clots in veins, prevent stroke and embolism in people with non ...

7. Discovery and development of direct Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Discovery_and_development...

   Discovery and development of direct Xa inhibitors. Four drugs from the class of direct Xa inhibitors are marketed worldwide. Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008. [1] The second one was apixaban (Eliquis), approved in Europe in 2011 [2] and in the United States ...